Since the recruitment to our study, the recommendations for the treatment of HF have been modified; in our group, patients were not treated with SGLT2 inhibitors, which we now know through their glucose and natriuretic effects have a beneficial effect on breaking DR [32]. The gene discussed is SLC5A2; the disease is hydrops fetalis.